BioREtain

BioStem Announces Notice of Allowance for Three New U.S. Patent Applications

May 28, 2025

Expanding patent portfolio reinforces the Company’s commitment to wound care innovation, with 55 issued patents and 52 pending applications POMPANO BEACH, Fla., May 28, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance...

BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting

May 1, 2025

Company to co-exhibit with strategic partner Venture Medical, LLC, highlighting collaborative innovation in chronic wound care management Three accepted scientific posters will feature BioStem’s advanced allograft portfolio POMPANO BEACH, Fla., May 1, 2025 - PRiSM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced its agenda for the...

BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025

Apr 30, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., April 30, 2025 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will release its first quarter 2025 financial results on Monday, May 12, 2025, and will host a conference call and webcast at 4:30 PM ET. The webcast will feature an overview of the...

BioStem Technologies Announces Extension to File 2024 Annual Report with OTC

Apr 1, 2025

POMPANO BEACH, Fla., April 1, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces it has filed for an extension to submit its annual report for the year ended December 31, 2024 to the OTC The company is currently undergoing a mandatory Securities Exchange Commission (SEC) review process related to its Form 10 registration...

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

Jan 13, 2025

POMPANO BEACH, Fla., January 13, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced selected preliminary financial results for the fiscal fourth quarter and full year ended December 31, 2024. 2024 Preliminary Fourth Quarter and Year End Results: Fourth quarter net revenue is expected to...

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

Jan 8, 2025

Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., January 8, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces the initiation of the BR-AM-DFU (BioREtain® Amniotic Membrane - Diabetic Foot Ulcers) clinical trial to evaluate Vendaje® versus...

BioStem Technologies CEO to Present at Biotech Showcase 2025

Jan 2, 2025

Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025 POMPANO BEACH, Florida, January 2, 2025 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces that Jason Matuszewski, the Company’s Chief Executive Officer, will present a corporate overview and update at the Biotech Showcase 2025 conference, which is...

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

Oct 29, 2024

The pricing announcement from the Center for Medicare Services became effective on October 1, 2024, and allows BioStem to begin marketing initiatives with Venture Medical POMPANO BEACH, Fla., October 29, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces it will initiate a nationwide launch of Vendaje AC® with Venture Medical,...

BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 28, 2024

Conference Call and Webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., October 28, 2024 - PRISM MediaWire - BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that it will release its Third quarter 2024 financial results on Tuesday, November 12, 2024, and host a conference call and webcast at 4:30 PM ET to discuss the results. The webcast will...

BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

Oct 2, 2024

Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth The study will be conducted in 60 patients at 10 sites across the U.S. and the first patients have begun treatment POMPANO BEACH, Florida, October 2, 2024 - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound...

NEWSROOM

BioStem Announces Notice of Allowance for Three New U.S. Patent Applications

BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting

BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025

BioStem Technologies Announces Extension to File 2024 Annual Report with OTC

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies CEO to Present at Biotech Showcase 2025

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

Contact Us